Biomea Fusion (BMEA) Stock Price

Biomea Fusion Price

NASDAQ·CLOSED
1.42
​
Market closed

Biomea Fusion stock price

Access this data via the Eulerpool API

Biomea Fusion business model & stock analysis

Biomea Fusion, Inc. is a hematological oncology biopharmaceuticals company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers and metabolic disorders. The company is headquartered in Redwood City, California and currently employs 103 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The firm has built FUSION System discovery platform to advance a pipeline of covalent small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical covalent programs for the treatment of select cancers.

Frequently asked questions about Biomea Fusion

13 analysts currently rate the Biomea Fusion stock: 11 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Biomea Fusion to generate revenue of 3.00 M USD and earnings per share of -0.75 USD.

Converted at the current exchange rate, the Biomea Fusion share trades at 1.27 EUR (1.42 USD).

The Biomea Fusion share (BMEA) is listed on 1 stock exchanges, including: NASDAQ (BMEA).

The expected revenue of Biomea Fusion is 3.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biomea Fusion is -54.01 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biomea Fusion is currently -1.90. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biomea Fusion stock.

The price-to-sales ratio (P/S) of Biomea Fusion is currently 34.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biomea Fusion stock.

The Eulerpool Quality Score for Biomea Fusion is 2/10.

The ISIN of Biomea Fusion is US09077A1060. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Biomea Fusion is BMEA. The ticker symbol is used to trade Biomea Fusion shares on the stock exchange.

Fair ValueTerminal
1.24 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Apr 16, 2021
ISIN
US09077A1060
Cusip
09077A106
Market capitalization
100.39 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-1.90
P/Ee 2027
-1.48
P/Ee 2028
-1.85
P/Ee 2029
-1.82
P/Ee 2030
-2.02
P/S
P/Se
34.22
EV/EBIT
—
P/B Ratio
3.40
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-198.44 %
Last updated Oct 13, 2026, 4:45 AM

Biomea Fusion Peer Group

Biomea Fusion Ticker

NASDAQ · BMEA

Biomea Fusion FIGI

BMEA:US · BBG00YS4WDC9BMEA:UA · BBG00ZV1VSZ1BMEA:UC · BBG00ZV1VT07BMEA:UN · BBG00ZV1VT25BMEA:UP · BBG00ZV1VT34BMEA:UB · BBG00ZV1VT52BMEA:UM · BBG00ZV1VT70BMEA:UX · BBG00ZV1VT89BMEA:UD · BBG00ZV1VTF1BMEA:UW · BBG00ZV1VTH9BMEA:UF · BBG00ZV1VTJ7BMEA:VY · BBG00ZV1VTK5

All fundamentals and in-depth analysis of Biomea Fusion

Our stock analysis for Biomea Fusion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomea Fusion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.